
    
      The target population is composed by patients who have confirmed adenocarcinoma of the rectum
      which is T3-4, N any, or locally unresectable, with tumor distal margin within 10 cm of the
      anal verge, with no evidence of distant metastatic disease, ECOG performance 0-1, and
      adequate bone marrow, renal and hepatic function.
    
  